Slide 1: Next-generation assistive technology and data measurement
Next-generation assistive technology and data measurement COFFEE MICROCAPS PRESENTATION JEREMY STEELE, CEO 8 NOVEMBER 2024 CONTROLBIONICS.COM | ASX:CBL
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subje ct m atte r cove re d in it. The inform ation in th is p re se n tation , wh e th e r writte n or ve rbal, has be e n pre pare d without taking into account the co
Slide 3: On the cusp of rapid global growth
INTRODUCTION On the cusp of rapid global growth A proven medical device company with sizeable global sales of core products that we design and manufacture 20 ye a rs o f Regulatory Co re b u sin e ss Blu e sky a n d Ma n y le ve rs fo r Ne a r ca sh flo w e xp e rtise with o u r cle a ra n ce a n d
Slide 4: Core IP Technology
CONTROL BIONICS. Core IP Technology
Slide 5: The evolution of our core IP
INTRODUCTION The evolution of our core IP Smaller, wireless and wearable NEUROEDUCATOR NEUROSTRIP One of the first prototype systems in A wire le ss, we a ra b le Ne u ro No d e wa s Ju st la u n ch e d in 2023, th e Ne u ro Strip th e Ne u ro EDUCATOR se rie s wa s first la u n ch e d in 2017. Usin
Slide 6: EMG technology: the heart of our solutions
INTRODUCTION EMG technology: the heart of our solutions
Slide 7: EMG technology: how it works
INTRODUCTION EMG technology: how it works An EMG sign a l is Ou r p a te n te d co d e d e te cte d . cre a te s a “switch ” to o p e ra te d e vice s Yo u r b ra in se n d s a To m o ve yo u r fin ge r, Our core IP uses smart Use rs ca n typ e , ge n e ra te th o u gh t like “m o ve m y a n e le ct
Slide 8: Markets
Markets Assistive Communication Assistive Mobility Data Measurement
Slide 9: Our fastest near term path to growth
ASSISTIVE COMMUNICATION Recent Win # 1: Granting of new US insurance code so device can be sold Our fastest near term path to growth separately from 1 Oct 24. First sales already received. Impact: Retail: Immediate price increase What Is It Wo rks like a switch th a t tu rn s in to a m o u se click,
Slide 10: The world's first autonomous wheelchair
ASSISTIVE MOBILITY The world’s first autonomous wheelchair What Is It A patent -pending module, developed with Deakin University, retrofits powered wheelchairs for safer, independent home travel controlled by the user's intentions Recent Wins: TGA approval granted. Market Size Minimum $100m globally
Slide 11: The new NeuroStrip is a game-changer
BEYOND ASSISTIVE TECHNOLOGY The new NeuroStrip is a game-changer
Slide 12: Blue sky potential with endless uses
BEYOND ASSISTIVE TECHNOLOGY NEUROSTRIP Near Term Catalysts: Announcement of new partnerships and first sales in Blue sky potential with endless uses the US sports science segment. What Is It A wo rld -first a ll-in -o n e a cce le ro m e te r a n d EMG d e vice th a t m e a su re s p h ysio lo gica
Slide 13: Financial Performance
CONTROL BIONICS. Financial Performance
Slide 14: Record sales pipeline, building FY25 momentum
FINANCIALS REVENUE (A$ m) EBITDA ($A m) Record sales pipeline, building FY25 momentum • FY24 revenue hit by ~$1M in NDIS delays. However, Q1 FY25 has seen a rapid turnaround in NDIS approvals with record processing from our largest -ever backlog. • Record Q4 results in the USA following improvement
Slide 15: How our sales are funded
ASSISTIVE COMMUNICATION How our sales are funded At least 75% of our sales are USA AUSTRALIA through a person’s insurer Medicare / Medicaid / Veteran Affairs / STAPP (Texas) National Disability Insurance Scheme ‘* Outsource to third -party biller who collects from the insurer (both public and privat
Slide 16: Continue to focus on growth, diversification and innovation
FINANCIALS Continue to focus on growth, diversification and innovation • Goal: Achieve near-term EBITDA-positive operations in all key geographic markets for our primary disability business. • Plan for FY25: Diversify into new products and markets to drive additional growth. • Diversifying with Neur
Slide 17: Recent wins and future roadmap
GROWTH STRATEGY Recent wins and future roadmap Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 DROVE TGA approval Ne w US in su ran ce code Japan b re ake ve n e xp e cte d Final tranche of US FDA subm ission for ap p rove d for Ne u roNode , re se arch grant paym e nt DROVE e n ab lin g a n e w US whole sa
Slide 18: Company
CONTROL BIONICS. Company
Slide 19: Experienced leadership
Experienced leadership BOARD • Ove r 20 ye a rs e xp e rie n ce in a ccou n tin g, a u d itin g a n d fin a n ce role s in th e Un ite d Sta te s a n d Au stra lia • Pre viou sly h e ld se n ior fin a n ce p osition s with m u lti- n a tion a l ASX-liste d a n d te ch n ology sta r t-u p e n titie s
Slide 20: Corporate Summary
Corporate Summary FINANCIAL INFORMATION Share price (6/11/24) A$0.06 Tightly held register. The recent capital Shares on issue (16/10/24) 247.56 m illion raise has provided the business with Market capitalisation sufficient funding well into FY26. A$14.85 m illion Cash (30/09/24) A$0.646 m illion Un
Slide 21: Get In Touch
Get In Touch COMPANY INVESTOR RELATIONS JEREMY STEELE JOE DURAK CEO EXECUTIVE DIRECTOR & FOUNDER CONTROL BIONICS LYNX ADVISORS jsteele@controlbionics.com jo e @lyn xa d vis o r s .c o m .a u +61 433 229 470 +6 1 4 1 4 4 6 5 5 8 2 CONTROLBIONICS.COM | ASX:CBL